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ophthalmology and neurology departments was especially studied. The pharma-
coeconomic evaluation was performed using a direct cost comparison analysis, in 
which MAbs cost is compared (2011-2014) to total drug cost per department, total 
in-patent drug cost, in-patent antibiotics cost and anti-HIV drug cost. The cost sav-
ing of Central Cytostatic Drug Preparation Unit operation for the year 2014 was 
especially studied. The analysis was performed in Euros (€ ) and drug cost was based 
on average hospital prices in Greece (official price lists). Results: Data analysis 
revealed that MAbs relative cost showed an augmentative trend throughout the 
study period (from 12.6%, 2008 to 13.45%, 2014). MAbs cost for all studied clin-
ics, with the exception of ophthalmology and hematology departments, showed 
minor decline. In-patent antibiotics and anti-HIV drugs represented a substantial 
and ongoing category of cost burden prescribed drugs (from 6.18%, 2011 to 9.98%, 
2014 and from 13.04%, 2011 to 21.44%, 2014 respectively). ConClusions: From 
2008 to 2012, though a substantial reduce of hospital pharmaceutical expenditure 
was obtained, due to memorandum obligations, an increase in MAbs consumption 
was detected (from 12.6% to 13.45%of total drug cost).The average hospital prices 
for all drugs were reduced for the same period. The total cost saving is mainly due 
both to generics and off-patent drugs use and drugs’ price negotiations supported 
with an obligated by the Ministry of Health 5% and 6.5 % rebate for in-patent drugs.
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objeCtives: In a randomized, double blind, controlled phase IV trial 
(ADACTA)*,Tocilizumab (TCZ) demonstrated superiority vs Adalimumab (ADA) in 
monotherapy, reducing signs and symptoms of rheumatoid arthritis (RA) in patients 
by whom methotrexate (MTX) is not tolerated or for whom it is inappropriate.The 
aim of this analysis was to evaluate the cost per response and the cost per disease 
remission of TCZ vs ADA in an RA monotherapy setting from the Italian Hospital 
perspective. Methods: TCZ-IV (intra-venous-8mg/kg monthly) and ADA-SC (sub-
cutaneous-40mgQ2W) monotherapy were compared, using efficacy results from 
ADACTA trial, in terms of cost per response (American College of Rheumatology-
ACR20-50-70) and cost per remission for both Disease-Activity-Score (DAS28< 2.6) 
and Clinical-Disease-Activity-Index (CDAI≤ 2.8). Treatment costs were considered 
(drug acquisition, administration and monitoring), obtained from published sources. 
Drug acquisition cost was derived from the ex-factory price. Drug administration 
cost (TCZ-IV only) was based on the cost for nursing and medical staff required for 
each infusion; monitoring visits and tests were considered as one per month for 
TCZ-IV and one every three months for ADA-SC.The analysis was conducted from 
the Hospital perspective and the time horizon was 24 weeks. Results: Compared 
with ADA, TCZ resulted dominant (more effective and less costly). The cost per 
response was lower with TCZ than with ADA: ACR20: € 10,494.5 and € 12,533.4;ACR50: 
€ 14,452.2 vs € 22,271.5;ACR70: € 20,989.1 and € 34,589.3 respectively. The cost per 
remission was € 17,096.4 vs € 58,966.6 for DAS28< 2.6 and € 39,659.6 vs € 66,575.2 for 
CDAI≤ 2.8 for TCZ vs ADA respectively. ConClusions: According to this analysis, 
in Italy TCZ monotherapy can be considered as an efficient strategy compared to 
ADA for treating RA patients intolerant to MTX or for whom MTX is inappropri-
ate. *Gabay C,Emery P,van Vollenhoven R,Dikranian A,Alten R,Pavelka K,Klearman 
M,Musselman D,Agarwal S,Green J,Kavanaugh A; ADACTA Study Investigators.
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of 
rheumatoid arthritis (ADACTA):a randomised,double-blind,controlled phase 4 trial. 
Lancet 2013;381(9877):1541-50
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objeCtives: Gout is a urate crystal deposition disease caused by chronic high serum 
uric acid (sUA) levels (i.e., hyperuricemia), resulting in painful flares and tophi. 
Treatment guidelines recommend maintenance of sUA levels < 6 mg/dL; however, 
sUA often remains elevated because of lack of, or inadequate response to therapy. Our 
goal was to understand the relationship between gout control and economic burden 
and to explore the impact of comorbidities. Methods: Data are from the combined 
2012 and 2013 US National Health and Wellness Survey (NHWS), a representative, 
cross-sectional general health survey (2012, n= 71,157; 2013, n= 75,000) of which 3729 
individuals self-reported a gout diagnosis (n= 344 controlled [sUA ≤ 6 mg/dL and 
no flares in past year], n= 2215 uncontrolled [sUA> 6 and/or ≥ 1 flare], and n= 1170 
unknown). Estimated total cost was calculated by adding direct cost (e.g., resource use) 
and indirect cost (e.g., work productivity loss). Those with gout + comorbidities (e.g., 
cardiovascular disease [CVD]) and their relationship with total cost were also exam-
ined. Multivariable generalized linear models were used to control for demographic 
and health characteristics to assess unique burden of uncontrolled gout. Results: 
Adjusted models indicate that those with controlled gout do not statistically differ 
from non-gout subjects. Those with uncontrolled gout reported significantly higher 
total annualized costs than non-gout subjects. Although uncontrolled gout had higher 
total cost than controlled gout, the difference was not significant. Similar patterns 
were observed for gout control and comorbidities. Those with uncontrolled gout + 
comorbidity (diabetes or CVD) reported higher total costs than those without gout or 
their respective comorbidity. There was no statistical difference for those with con-
trolled gout + comorbidity versus those without gout or comorbidity. ConClusions: 
Uncontrolled gout results in higher total costs than for non-gout patients. Controlled 
gout patients have lesser burden—closer to non-gout subjects. Total cost for uncon-
trolled gout may be further exacerbated by comorbidities.
perspective. Results: The difference in cost per response between the alternatives 
was in favor of tocilizumab in all three scenarios examined. In more detail, the 
savings generated by the use of tocilizumab associated with achieving ACR 70 for a 
68kg (mean weight) patient were € 12,529, € 9,657 and € 8,810 from the hospital, health 
system and society’s perspective, respectively. Similarly, the savings regarding DAS 
28≤ 3.2 were € 14,838, € 13,041 and € 12,506 for each perspective respectively. In the 
third scenario (DAS 28< 2.6) the difference in cost per response between tocilizumab 
and adalimumab was € -32,811 from the hospital’s, € -30,522 from the health system’s 
and € -29,831 from the society’s perspective. Results indicate that treating patients 
with tocilizumab IV yields sufficient savings to initiate more patients in treatment 
with tocilizumab in 1L monotherapy and to achieve low disease activity or remission 
with greater probability and less resources. ConClusions: Choosing tocilizumab 
instead of adalimumab as a 1L monotherapy for the RA treatment could be proven 
to be a cost-saving option, with increased significance in the current economic 
environment of restricted healthcare resources and significant budget constraints.
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objeCtives: Non-steroidal anti-inflammatory drugs (NSAIDs) increase vascular 
and gastrointestinal risks. These risks have not been described with chondroitin 
sulphate (CS). This study aims to evaluate the economic impact of osteoarthri-
tis (OA) treatment with CS versus NSAIDs for the Public Healthcare System in 
Catalonia (Spain). Methods: An economic model was developed to estimate the 
health and economic impact of ethical CS prescription due to the avoidance of gas-
trointestinal adverse events (GIAE) and coronary ischemic events (CIE) associated 
with NSAIDs. The estimated population with knee and hands OA was calculated 
from EPISER study, population official data (age ≥ 20 years) and a population-based 
drug utilization study in patients with OA. The annual probabilities of suffer-
ing GIAE and CIE with CS and NSAIDs were obtained from a systematic review 
of medical literature, published meta-analysis and previous economical study 
(VECTRA). Direct healthcare costs (€ 2015) included drug acquisition, GIAE and 
CIE management. Other adverse events associated with NSAIDs with economic 
impact (renal failure, ischemic stroke, liver failure) were not considered in the 
model. Deterministic sensitivity analyses of the extreme values of all variables 
were undertaken. Results: It is estimated that each year 300,000 and 72,000 OA 
patients are treated with NSAIDs and CS, respectively, in Catalonia with a cost of 
11 and 4 million euros. Because 72,000 OA patients are treated with CS instead 
of NSAIDs, 19,222 mild-moderate and 649 severe episodes of NSAID-related GIAE 
and 39 CIE episodes would be avoided annually. The annual savings by avoiding 
GIAE and CIE episodes is estimated at 6.2 million euros and € 493,000, respectively. 
Sensitivity analyzes confirmed the robustness of the results. ConClusions: OA 
treatment with chondroitin sulphate could reduce the health care costs for the 
Public Healthcare System due to the decreased rate of gastrointestinal and car-
diovascular adverse events compared with NSAIDs.
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objeCtives: Pain after arthroplasty is a common condition which can result in 
loss of quality of life and significant financial burden. This study aims to evaluate 
extended-release oxycodone versus morphine in an “if necessary” regime in the 
management of pain post-arthroplasty, from the Brazilian public and private health-
care systems perspectives. Methods: A decision model was developed to analyze 
two scenarios. In both, patients in group 1 received extended-release oxycodone 
and immediate-release opioid. Regarding group 2, in scenario 1, patients received 
immediate-release opioid and, in scenario 2, immediate-release opioid and placebo. 
Efficacy data were obtained from Beer et al., 2005 (scenario 1) and Cheville et al., 2001 
(scenario 2). Direct costs were obtained from official prices lists. In scenario 1, time 
horizon was related to a 3-week treatment period and, in scenario 2, determined by 
the hospitalization period. Discount rates were not applied. Univariate sensitivity 
analysis was performed to evaluate different hospital categories. Results: Total 
costs from the public perspective were 1,486 BRL and 1,520 BRL per patient treated 
in scenario 1, and 3,299 BRL and 3,591 BRL per patient treated in scenario 2, in groups 
1 and 2, respectively. From the private perspective, total costs in scenario 1 were 
3,132 BRL and 3,457 BRL per patient treated and 7,197 BRL and 8,181 BRL per patient 
treated in scenario 2, in groups 1 and 2, respectively. In the univariate sensitivity 
analysis, all evaluated scenarios remained consistent and favorable to the use of 
extended-release oxycodone. ConClusions: The inclusion of extended-release 
oxycodone can result in reduction of hospitalization costs, which would lead to 
resource savings for the payer.
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objeCtives: To assess the cost of monoclonal antibodies in an Athens/Greece ter-
tiary hospital in a seven year cost comparison analysis and to compare results to 
other in-patent drug categories. Methods: In this study (2008-2014) monoclonal 
antibodies (MAbs) consumption in Evaggelismos hospital (931-beds) was assessed. 
MAbs consumption/cost in hematology, oncology, rheumatology, gastroenterology, 
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forms of exit from work are included this figure rises to 617,764 YWLL (disability: 
121,323; unemployment: 106,502). A total number of 684,960 PYWLL were esti-
mated (401/1000) if early retirement is considered and 1,186,679 PYWLL (695/1000) 
for all forms of exit from work. The mean YWLL and PYWLL inactivity ratios were 
13% and 25%, respectively. ConClusions: We observed a high stock of accumu-
lated YWLL caused by RD in Portugal. Moreover, if nothing is done otherwise the 
amount of working life still to be lost from the current early retirees due to RD 
will almost equal those already gone, meaning that health policies should target 
not only job retention measures but also return-to-work ones.
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objeCtives: This study investigated the characteristics of the female osteoporosis 
population with increased fracture risk as defined by German guidelines and evalu-
ated the imminent (1-year) risk for fracture and the associated burden. Methods: 
This observational study used retrospective German sick fund data (~5% of the 
population). The sample was defined based on 2010 data while the study inves-
tigational year was 2011.Women with osteoporosis (WO) were considered to be 
at increased risk (IR) of fracture if they had at least one prescription for antire-
sorptive/anabolic drug, a history of osteoporotic fracture, or were identified with 
a condition or medication outlined in the German guideline. WO not meeting any 
of these criteria were considered “non-IR”. Descriptive analyses on osteoporosis 
related hospitalization, fracture frequency and osteoporosis related costs were per-
formed. Results: Among 74,974 WO, 39,969 (53.3%) were identified as being at IR. 
The mean age (SD) in the IR and non-IR group was 75.2 (9.5) and 74.0 (10.1) years, 
respectively. Approximately half of the IR patients received osteoporosis medica-
tion (43% bisphosphonate, 2.7% strontium, 0.9% denosumab, 1.5% raloxifen, 0.3% 
teriparatide). Estimated osteoporotic fracture occurrence was substantially higher 
in IR than in non-IR (9,647 vs 122 fracture events). IR patients were hospitalized at 
a higher rate compared to non-IR patients (14.8% vs 6.5%). Mean (SD) and median 
(IQR) annual osteoporosis-related costs (medication, hospitalization, outpatient 
treatment) were 1,405€ (3,193€ ) and 435€ (622€ ), respectively, for IR patients and 
640€ (2,110€ ) and 225€ (237€ ) for non-IR patients. ConClusions: Approximately 
half of the osteoporosis population met increased risk definition criteria. A note-
worthy proportion of these patients are at imminent risk for fracture based on the 
observed fracture events over a 12 months’ follow up. Despite being responsible for 
a disproportionately large disease burden and related health care costs less than 
half of the IR patients received medication for their osteoporosis.
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objeCtives: We aim to estimate indirect costs of early retirement caused by RD 
in Portugal. Methods: We used individual level data from the national, cross-
sectional, population-based EpiReumaPt study (Sep2011-Dec2013). 10,661 inhabit-
ants were randomly surveyed in order to capture and characterize all cases of RD 
within a representative sample of the Portuguese population. In this analysis we 
used all participants aged between 50 and 65 years old (yo), near the official retire-
ment age. An official national database was used to calculate productivity values 
by gender, age and region, using the human capital approach. All results were based 
on weighted data. Results: 29.9% of the Portuguese population with ages between 
50 and 64 yo were officially retired. Among these, 13.1% were retired due to RD. The 
estimated annual indirect cost following premature retirement caused by RD was 
€ 910 million (€ 555 per capita; € 1,625 per self-reported RD patient and € 13,592 per 
early retiree due to RD). Females contributed with 84% for these costs (€ 766 million; 
€ 882 per capita versus € 187 from males). The mean retirement age for early retirees 
due to RD was 54.8 yo. Thus, we estimate an average indirect cost of € 138,635 per 
early retiree due to RD until official retirement age (assuming 65 yo and fixed annual 
productivity values). Moreover, RD may underlie early retirement even when RD is 
not self-reported to be its cause, since we also found an independent association 
between all registered early retirement and self-reported RD (adjusted OR: 1.41; CI: 
1.03-1.95; p= 0.031), meaning that RD might further contribute for this sort of indirect 
costs. ConClusions: Early retirement caused by RD amounts to approximately 
0.5% of the national GDP 2013. The public health concern and the economic impact 
highlight the need to prioritize investments in health and social protection policies 
targeting patients with rheumatic conditions.
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objeCtives: To estimate annual health care resource utilization and direct medi-
cal cost for patients with osteoporotic fractures in Tianjin, China. Methods: Data 
were obtained from Tianjin Urban Employee Basic Medical Insurance database. 
Patients who ≥ 50 years old, with ≥ 1 diagnosed of osteoporotic fractures between 
2009 and 2010, and 12-month continuous enrollment before (baseline) and after 
(follow-up) the first observed osteoporotic fracture diagnosis were identified. Both 
osteoporosis-related and all-cause health care resource utilization and direct 
medical cost were estimated during the 12-month follow-up period. Ordinary 
least square regression model was applied to identify factors associated with 
the direct medical cost. Results: A total of 5941 patients were included, with 
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objeCtives: To investigate the cost per retention year for ustekinumab (UST) rela-
tive to infliximab (INF) in first line treatment of psoriatic arthritis (PsA) in Russian 
plaque psoriasis patients (PSO). Methods: A 10 year Markov model was con-
structed with UST and INF as first line biologic therapies and a two-step rescue 
therapy consisting of adalimumab (ADA) as the second line biologic for both treat-
ment arms and non-biologic supportive care of oral methotrexate 15mg/week (BSC) 
if the patient fails ADA. Transition probabilities were obtained from PSOLAR, an 
observational longitudinal study studying the safety of biologics in PSO and PsA, by 
fitting 5-year time-on-treatment data for self-identified PsA patients with confirmed 
PSO to a Weibull model and extrapolating over 10 years. All patients were assumed 
to have failed prior non-biologic therapy and retention on therapy was used as 
the target endpoint. Direct treatment costs were calculated from the perspective 
of the Russian Ministry of Health, converted to 2014 euros (1 RUB = € 0.0197) and 
discounted at 5%, as per Russian pharmacoeconomic guidelines. Results: Over a 
10 year horizon, INF-ADA-BSC was associated with a higher cost and a lower amount 
of retention years while the UST-ADA-BSC treatment line gives an additional 0.68 
biologic retention years per patient and a potential savings of € 29370 per patient 
with ustekinumab as first-line biologic treatment. However, these results were 
sensitive to changes in biologic drug prices and by extension, the market share of 
biosimilars. ConClusions: An increased retention time is usually correlated with 
higher patient satisfaction levels as well as response and safety. According to our 
model, initiating biologic therapy with ustekinumab is cost saving compared to the 
current first choice biologic, infliximab. However, further research has to be initiated 
to quantify the relationship between increased patient retention and additional gain 
in treatment response and safety.
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objeCtives: Ankylosing spondylitis (AS) is a form of spondyloarthritis with chronic 
inflammatory involvement of axial skeleton, variable peripheral joints and nonar-
ticular structures. The objective of this study was to determine the costs comparing 
patients under biologic therapy (BT) with those in conventional treatment (CT), 
under Brazilian private health care system’s perspective. Methods: We studied 6.5 
million members of a proprietary claim database, from January 2009 to December 
2012. Approximately 0.04% (2,626) was patients with ICD-10 AS-related. Most of them 
were from private health care plans. All medical out-patients and in-patients treat-
ment costs were studied, including drugs and ancillary diagnostic tests. Results: 
The females comprise 52% of this cohort, and 73.8% of them were between 18 and 
49 years old. Around 2,626 patients were treated, being 2,492 with CT and 134 with 
BT, primarily anti-TNF therapy.About 74% treated with CT presented any comor-
bidity, while 0.75% of those treated with BT. The total costs were USD3,668 for CT 
and USD4,575 for BT, with mean patient costs of USD1,980 for CT and USD4,575 for 
BT. The average hospitalizations costs for comorbidities were USD1,106, stressing 
that many of them were gastrointestinal complications of the disease. The average 
hospitalization costs under CT was USD7,988, considering under BT was USD1,271. 
The average days of hospitalization were 4.83 and 3.1 days for CT and BT, respec-
tively. The total costs of hospitalization of CT was USD511,217 being 62% due to 
materials (e.g., prosthesis) and USD25,428 for BT, being 17% due to materials and 
66% due to room rates and equipment rental. ConClusions: In this Brazilian pri-
vate claim database, BT had lower direct costs for hospitalizations and probability 
of comorbidities, when compared to CT. Although the mean patient cost with BT 
is higher than with CT, the lower probability of comorbidities occurrence with BT 
may justify its choice.
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objeCtives: The aim of this study was to calculate the years of working life lost 
(YWLL) caused by rheumatic diseases (RD). Methods: We used data from the 
cross-sectional, population-based EpiReumaPt study (Sep2011-Dec2013). 10,661 
inhabitants were randomly surveyed to capture all cases of RD within a represent-
ative sample of the Portuguese population. We analyzed participants aged between 
50 and 65 years old (yo), near the official retirement age. YWLL were determined 
for cases with premature retirement caused by RD (self-reported) estimated as 
the difference between each participant’s age and the respective retirement age 
(“observed stock”), while the potential YWLL (PYWLL: YWLL+“expected stock” of 
YWLL still to occur if there is no return-to-work) was the difference between 
official and actual retirement ages. We also calculated the percentage of time in 
inactivity (inactivity ratio = YWLL/Active age-range [15-65yo]). All results were 
based on weighted data. Results: 3.9% (n= 66,953/N= 1,706,750) of the Portuguese 
population (50-64 yo) had premature retirement caused by RD. The mean age of 
early retirement caused by RD was 54.8 yo, which led to a total stock of 389,939 
YWLL (228 per 1000 inhabitants). Women account for 85% of these YWLL. If all 
